68Ga-cyc-DX600 PET/CT在ACE2靶向肿瘤显像中的应用
本研究合成68Ga-cyc-DX600作为ACE2 PET示踪剂,用NOD-SCID小鼠皮下肿瘤模型验证ACE2特异性,并行免疫组化和蛋白质印迹认证,随后在四例癌症患者中与FDG PET比较。示踪剂摄取与ACE2表达呈确定依赖(r=0.903,p<0.05),患者中ACE2 PET与FDG PET定量值呈负相关,提示ACE2 PET可作为FDG PET糖代谢显像的补充。
要点
- 68Ga-cyc-DX600的代谢清除在60分钟内初步完成,实现ACE2依赖的器官特异性背景。
- 皮下肿瘤模型的示踪剂摄取与ACE2表达呈确定依赖(r=0.903,p<0.05)。
- 患者中ACE2 PET与FDG PET定量值呈负相关,提示互补价值。
核心结论
- 68Ga-cyc-DX600 PET是一种ACE2特异性显像,用于肿瘤鉴别诊断,并为FDG PET等常规核医学糖代谢诊断提供补充价值。
研究设计与样本
- 研究合成68Ga-cyc-DX600作为ACE2 PET示踪剂,使用NOD-SCID小鼠制备HEK-293或HEK-293T/hACE2细胞皮下肿瘤模型验证ACE2特异性。
- 研究用其他种类肿瘤细胞评估对ACE2表达的诊断效能,并用免疫组化分析和蛋白质印迹认证ACE2 PET的发现。
- 研究在四例癌症患者中行ACE2 PET并与FDG PET比较。
主要发现
- 68Ga-cyc-DX600的代谢清除在60分钟内初步完成,实现ACE2依赖的器官特异性背景。
- 皮下肿瘤模型的示踪剂摄取与ACE2表达呈确定依赖(r=0.903,p<0.05),后者是ACE2 PET用于ACE2相关肿瘤鉴别诊断的主要因素。
- 一例肺癌患者注射后50和80分钟的ACE2 PET获得可比及的肿瘤-背景比。
- 一例食管癌患者的ACE2 PET与FDG PET定量值呈负相关(SUVmax:r=-0.971,p=0.006;SUVmean:r=-0.994,p=0.001),无论原发灶或转移灶。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: For the tumor-specific ACE2 expression, this research aimed to establish and verify ACE2-targeted PET imaging in differentiating tumors with distinct ACE2 expression. METHODS: 68Ga-cyc-DX600 was synthesized as tracer of ACE2 PET. NOD-SCID mice were used to prepare the subcutaneous tumor models with HEK-293 or HEK-293T/hACE2 cells to verify ACE2 specificity, with other kinds of tumor cells to evaluate the diagnostic efficiency for ACE2 expression, additionally, immunohistochemical analysis and western blot were used to certify the findings on ACE2 PET, which was then performed on four cancer patients and compared with FDG PET. RESULTS: The metabolic clearance of 68Ga-cyc-DX600 was initially completed in 60 min, realizing an ACE2-dependent and organ-specific background of ACE2 PET; meanwhile, tracer uptake of subcutaneous tumor models was of a definite dependence on ACE2 expression (r = 0.903, p < 0.05), and the latter served as the primary factor when ACE2 PET was used for the differential diagnosis of ACE2-related tumors. In pre-clinical practice, a comparable tumor-to-background ratio was acquired in ACE2 PET of a lung cancer patient at 50 and 80 min post injection; the quantitative values of ACE2 PET and FDG PET were negatively correlated (r = - 0.971 for SUVmax, p = 0.006; r = - 0.994 for SUVmean, p = 0.001) in an esophageal cancer patient, no matter the primary lesion or metastasis. CONCLUSIONS: 68Ga-cyc-DX600 PET was an ACE2-specific imaging for the differential diagnosis of tumors and added complementary value to conventional nuclear medicine diagnosis, such as FDG PET on glycometabolism.
引用
- Ren F, Jiang H, Shi L, et al. 68Ga-cyc-DX600 PET/CT in ACE2-targeted tumor imaging. Eur J Nucl Med Mol Imaging. 2023. PMID: 36847824. doi:10.1007/s00259-023-06159-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。